10-Q: IMAC Holdings Reports Second Quarter 2024 Results, Transitioning to Precision Medicine

IMAC Holdings reports a net loss of $1.79 million for the six months ended June 30, 2024, as it transitions from regenerative medicine to precision cancer treatment.

Summary

• IMAC Holdings has transitioned its focus from regenerative medicine to precision medicine in cancer treatment, acquiring laboratory capabilities from Theralink Technologies, Inc.
• The company reported a net loss of $1.79 million for the six months ended June 30, 2024, compared to a net loss of $5.1 million for the same period in 2023.
• Revenues from continuing operations were $15,750 for both the three and six months ended June 30, 2024, derived from collaborations with biopharmaceutical companies.
• The company's working capital deficit increased to $3.3 million as of June 30, 2024, from $0.8 million at the end of 2023.
• IMAC Holdings sold 1,276, 17,364, 24,172 and 450 shares of Series C-2, Series D, Series E and Series F preferred stock, respectively, for gross proceeds of $1.35 million during the six months ended June 30, 2024.
• The company issued promissory notes for $1.4 million, receiving $1 million in proceeds, and also issued additional promissory notes for $840,000, receiving $600,000 in proceeds, after the reporting period.
• The company has a significant accumulated deficit of $57.7 million as of June 30, 2024.
• The company has identified substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company is making a strategic shift towards a promising area of precision medicine, the financial results are weak, with a significant net loss, increasing working capital deficit, and a going concern warning. The company's reliance on future capital raises and the uncertainty surrounding its ability to achieve commercial success contribute to a negative sentiment.

Positives

• The company has successfully transitioned its business focus to precision medicine in cancer treatment.
• The company's net loss from continuing operations decreased compared to the same period in the previous year.
• The company acquired laboratory capabilities and intellectual property licenses to engage in clinical testing of breast cancer patients.
• The company has secured collaborations with biopharmaceutical companies to identify drug targets based on activated protein analysis.
• The company has increased its cash position to $890,610 as of June 30, 2024, from $221,511 at the end of 2023.

Negatives

• The company has a significant accumulated deficit of $57.7 million.
• The company's working capital deficit increased to $3.3 million.
• The company has a substantial amount of current liabilities at $4.52 million.
• The company has incurred significant operating losses and cash outflows from operations.
• The company has identified substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to obtain additional financing for the projected costs associated with the asset purchase and personnel is uncertain.
• The company's ability to attract competent, skilled laboratory and sales personnel for its laboratory operations at acceptable prices is a risk.
• The company's ability to control operating expenses and prove the asset acquisition will be beneficial to the company and stockholders is a risk.
• The company is susceptible to risks relating to investigation or audit by the Centers for Medicare & Medicaid Services (CMS), health insurance providers and the IRS.
• The company's financial results could be adversely affected by liabilities from its discontinued operations.
• The company may fail to achieve and sustain commercial success for its services.
• The company faces intense competition in the cancer information field.
• The company may fail to retain key personnel.
• The company must rely on relationships with third-party suppliers to supply necessary resources used in its technology.
• The company's prospective revenues will be diminished if payors do not adequately cover or reimburse its services.
• Regulatory changes, such as proposed government regulation of Laboratory Developed Tests, could require the company to conduct additional clinical trials or result in delays, increased costs, or the failure to obtain necessary regulatory approvals.
• If the company is unable to safeguard against security breaches with respect to its information systems, its business may be adversely affected.
• The company is exposed to potential product liability claims, and insurance against these claims may not be adequate and may not be available to the company at a reasonable rate in the future.
• The company has exposure to general uncertainty and complex legal matters regarding the patents it licenses.
• If the company is unable to protect the proprietary rights it licenses or to defend against infringement claims, it may not be able to compete effectively or operate profitably.
• The company may be subject to litigation with respect to the ownership and use of intellectual property that will be costly to defend.
• The company may in the future be subject to patent litigation and may not be able to protect its intellectual property at a reasonable cost if such litigation is initiated.
• Obtaining and maintaining the company's patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and the company's patent protection could be reduced or eliminated for non-compliance with these requirements.
• The company may not be able to protect its intellectual property rights throughout the world.
• The company's stock price is volatile and an investment could decline in value.
• The company's issuance of preferred stock could adversely affect holders of Common Stock.
• The company is an emerging growth company and its election to delay adoption of new or revised accounting standards applicable to public companies may result in its consolidated financial statements not being comparable to those of some other public companies.
• The company may not be able to maintain the listing of its Common Stock on Nasdaq, which may adversely affect the flexibility of holders of Common Stock to resell their securities in the secondary market.
• If the company's product were to become the subject of concerns related to its efficacy, safety, or otherwise, its ability to generate revenues from its product could be seriously harmed.
• Adoption of the company's product for the analysis of patients with either early stage or advanced cancer may be slow or limited for a variety of reasons, including competing therapies and perceived difficulties in the treatment process or delays in obtaining reimbursement.
• To achieve global success for the company's product as a technology, it will need to obtain approvals by foreign regulatory authorities.
• The company's product in clinical development may be limited in use if it does not maintain or gain required regulatory approvals.
• The company could face competition from other technologies and products that could impact its profitability.
• The company uses hazardous materials in its business and must comply with environmental laws and regulations, which can be expensive.

Future Outlook

The company anticipates that it will need to raise additional capital to fund future operations and may seek additional capital due to favorable market conditions or strategic considerations.

Management Comments

• The company has acquired laboratory capabilities from Theralink Technologies, Inc, and has the technical capability and intellectual property licenses to engage in clinical testing of breast cancer patients to determine which medications and treatments will be most effective.
• The company also engages in collaborations with biopharmaceutical companies to identify drug targets based on activated protein analysis.
• Drug makers benefit from the application of our technology in target identification, clinical trial design, and clinical trial execution.
• Ultimately our technology will be used to both gain FDA approval for treatments and also determine which patients will most benefit from those treatments.

Industry Context

The company's transition to precision medicine aligns with the growing trend in the healthcare industry towards personalized treatments and targeted therapies, particularly in oncology. The company's focus on activated protein analysis and collaborations with biopharmaceutical companies positions it to capitalize on the increasing demand for advanced diagnostic and drug development tools.

Comparison to Industry Standards

• IMAC Holdings' transition to precision medicine is similar to other companies in the biotechnology sector that are focusing on personalized medicine and targeted therapies.
• Companies like Foundation Medicine and Guardant Health are also involved in genomic profiling and liquid biopsy technologies for cancer treatment, but IMAC Holdings is focusing on activated protein analysis.
• The company's financial results are not directly comparable to established biotechnology companies due to its early stage of development and recent transition.
• The company's working capital deficit and accumulated deficit are significant and highlight the challenges faced by early-stage biotechnology companies in achieving profitability.
• The company's reliance on collaborations with biopharmaceutical companies for revenue generation is a common strategy in the biotechnology industry, but it also carries risks related to the success of these collaborations.

Legal Proceedings

• The company is involved in ongoing audits based on its previous regenerative medicine business.
• The company is appealing a decision related to overpayments for Progressive Health & Rehabilitation, Ltd.
• The company is appealing a decision related to overpayments for Advantage Therapy.
• The company received a suspension of payment notification from Covent Bridge Group for IMAC Regeneration Center of Kentucky and is appealing the recommendation and outcomes of the audit by Kepro.
• The company received notification from Covent Bridge Group that it estimates The Ozzie Smith Center in St. Louis, MO was overpaid CMS funds and is planning to appeal by filing a redetermination request.
• The company and its subsidiary are in default in a foreclosure action regarding a lease for its former clinic location in Tampa, Florida.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential capital raises and the uncertainty surrounding the company's future.
• Employees may experience job insecurity due to the company's financial challenges and restructuring.
• Customers (biopharmaceutical companies) may be impacted by the company's ability to deliver on its collaborations.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to develop and commercialize its technology for precision medicine in cancer treatment.
• The company will seek to obtain additional financing to fund future operations.
• The company will work to obtain credentials for reimbursement for its Ignite test by Medicare and certain third-party payors.
• The company will continue to engage in collaborations with biopharmaceutical companies to identify drug targets based on activated protein analysis.

Key Dates

Keywords

precision medicine, cancer treatment, proteomics, biopharmaceutical, laboratory testing, activated protein analysis, clinical trials, preferred stock, promissory notes, financial results, going concern, Theralink Technologies, Medicare, FDA approval, warrants